TUCSON, AZ / ACCESSWIRE / June 3, 2021 / Aqualung Therapeutics, an early-stage biotech company developing an immune-focused, anti-inflammatory therapeutic platform for unchecked inflammation, a characteristic of serious acute and chronic diseases, will be participating in the first annual Acute Respiratory Distress Syndrome (ARDS) Drug Development Summit from July 13th-15th. This virtual summit includes several of the world's top experts on ARDS as faculty presenters including Aqualung's CEO Joe GN Garcia MD, former Chief of Pulmonary and Critical Medicine at Johns Hopkins University.
The coronavirus pandemic has catapulted ARDS into the limelight and offered a once in a lifetime opportunity to meaningfully study large patient populations with a homogenous disease - revolutionizing the notoriously challenging drug development landscape and widening the window of therapeutic opportunity to treat ARDS for the first time ever.
From analyzing the molecular mechanisms behind COVID-19-related ARDS and ARDS in general, to exploring the latest research on numerous therapies; the inaugural ARDS Drug Development Summit will be a platform for industry pioneers to strategize against the drug development challenges faced in COVID-19/non-COVID-19-associated ARDS and to catalyze a new wave of targeted therapies for pulmonary and systemic inflammation.
Sadly, there are still no FDA-approved therapies for ARDS despite over 2 million new ARDS cases annually on a global basis, and a mortality rate reaching 40%. This is a vexing medical condition and a significant unmet medical need. Dr Garcia will be one of 60 global experts to participate in this summit and new information will be presented on impressive efficacy of Aqualung's novel therapeutic drug, the humanized monoclonal antibody, ALT-100 mAb, as a potential treatment for ARDS and Covid-19-induced ARDS.
The development of ALT-100 mAb is based upon the identification by Aqualung Therapeutics scientists of extracellular NAMPT or eNAMPT, as a master regulator of tissue and systemic inflammation and as a novel therapeutic target in ARDS. The company has initiated ALT-100 mAb manufacturing and intends to execute human proof of concept studies within 8-10 months. "I am very much looking forward to sharing our latest extraordinarily exciting data that underscores the therapeutic capacity for targeting eNAMPT, a key contributor to runaway inflammation and cytokine storm, in the treatment of ARDS patients" states Joe GN Garcia MD. To participate in the event please see the link below to learn more.
ARDS Drug Development Summit | July 13-15 | Virtual Conference - Home (ards-summit.com)
About Aqualung Therapeutics Corporation
Aqualung is an early-stage biotech company developing immune-focused therapeutic antibodies for patients suffering from disorders characterized by acute and chronic lung and systemic inflammation. Founded in 2016 and led by a physician scientist, Aqualung's science-driven approaches led them to the identification of nicotinamide phosphoribosyltransferase (NAMPT) as a contributor to severe inflammatory diseases. Aqualung Therapeutics is developing eNamptor™, a Next Gen platform comprised of : i) ALT 100 mAb, a humanized eNAMPT-neutralizing monoclonal antibody; ii) eNAMPT-Plex, a plasma-based biomarker panel comprised of cytokines, including eNAMPT, which predicts ARDS mortality; and iii) NAMPT-Gene, a genotyping assay that identifies individuals at increased risk for ARDS death. The pipeline of ALT is designed to target a range of diseases, including ARDS, ventilator- and radiation-induced lung injury, chorioamnionitis, prostate cancer, pulmonary hypertension, and both pulmonary and hepatic fibrosis (NASH), conditions each with significant unmet medical needs and with significant morbidity and mortality. For additional information about the company, please visit www.aqualungtherapeutics.com.
Aqualung Therapeutics Corporation
www.aqualungtherapeutics.com
Tel: +1 (312) 618-7337
Joe GN Garcia MD
Email: [email protected]
SOURCE: Aqualung Therapeutics